Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia

References

• Depression and other common mental disorders: global health estimates; 2017 Available from:https://www.who.int/mental_health/management/depression/prevalence_global_health_estimates/en/. Accessed 1118, 2019.
   Google Scholar
• Pratt R, Stapelberg NJC. Early warning biomarkers in major depressive disorder: a strategic approach to a testing question. Biomarkers. 2018;23(6):563–572. doi:10.1080/1354750X.2018.146356329631432
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2013.
   Google Scholar
• De Berardis D, Fornaro M, Orsolini L, et al. Alexithymia and suicide risk in psychiatric disorders: a mini-review. Front Psychiatry. 2017;8:148. doi:10.3389/fpsyt.2017.0014828855878
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. doi:10.1016/S0140-6736(17)32802-729477251
   PubMed Web of Science ®Google Scholar
• Dirmaier J, Steinmann M, Krattenmacher T, et al. Non-pharmacological treatment of depressive disorders: a review of evidence-based treatment options. Rev Recent Clin Trials. 2012;7(2):141–149. doi:10.2174/15748871280010023322353197
   PubMedGoogle Scholar
• Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17(11):696–707. doi:10.1016/j.euroneuro.2007.03.00917521891
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7. doi:10.1016/j.jad.2013.10.04324314926
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990;51(Suppl):39–47.
   PubMedGoogle Scholar
• Kim N, Cho SJ, Kim H, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea. PLoS One. 2019;14(8):e0221552. doi:10.1371/journal.pone.022155231442296
   PubMed Web of Science ®Google Scholar
• Fife D, Feng Y, Wang MY-H, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. 2017;252:277–283. doi:10.1016/j.psychres.2017.03.00628288438
   PubMed Web of Science ®Google Scholar
• Howland RH. Sequenced treatment alternatives to relieve depression (STAR*D). Part 2: study outcomes. J Psychosoc Nurs Ment Health Serv. 2008;46(10):21–24. doi:10.3928/02793695-20081001-05
   Web of Science ®Google Scholar
• Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449–459. doi:10.1007/s11920-007-0061-318221624
   PubMedGoogle Scholar
• Trevino K, McClintock SM, McDonald Fischer N, Vora A, Husain MM. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry. 2014;26(3):222–232.25166485
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Asher G, Gartlehner G, et al. Definition of treatment-resistant depression in the medicare population. Agency for Healthcare Research and Quality (US); 2018 Available from: http://www.ncbi.nlm.nih.gov/books/NBK526366/. Accessed 1026, 2020.
   Google Scholar
• Ng CH, Kato T, Han C, et al. Definition of treatment-resistant depression - Asia Pacific perspectives. J Affect Disord. 2019;245:626–636. doi:10.1016/j.jad.2018.11.03830445388
   PubMed Web of Science ®Google Scholar
• Stata Statistical Software: release 15. [computer program]. College Station, TX: StataCorp LLC2017.
   Google Scholar
• NVivo Qualitative Data Analysis Software. [computer program] version 11. QSR International Pty Ltd; 2017.
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder; 2010 Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed 1118, 2019.
   Google Scholar
• Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55(8):694–700. doi:10.1001/archpsyc.55.8.6949707379
   PubMed Web of Science ®Google Scholar
• Maust D, Cristancho M, Gray L, Rushing S, Tjoa C, Thase M. Psychiatric rating scales In: Handbook of Clinical Neurology. Vol. 106 Elsevier; 2012:227–237.22608624
   PubMedGoogle Scholar
• Moore M, Ali S, Stuart B, et al. Depression management in primary care: an observational study of management changes related to PHQ-9 score for depression monitoring. Br J Gen Pract. 2012;62(599):e451–457. doi:10.3399/bjgp12X64915122687239
   PubMed Web of Science ®Google Scholar
• Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–659. doi:10.1016/s0006-3223(03)00231-212706951
   PubMed Web of Science ®Google Scholar
• Lam RW, McIntosh D, Wang J, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. disease burden and principles of care. Can J Psychiatry. 2016;61(9):510–523. doi:10.1177/070674371665941627486151
   PubMed Web of Science ®Google Scholar
• Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841–1853. doi:10.1038/sj.npp.130113116794566
   PubMed Web of Science ®Google Scholar
• CY YTL L, Chen CS. Treatment Guideline for Major Depressive Disorder in Primary Care. Taiwan Association Against Depression; 2012.
   Google Scholar
• Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179–200. doi:10.1016/s0193-953x(05)70283-58827185
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37.
   PubMedGoogle Scholar
• Taylor CB. How to Practice Evidence-Based Psychiatry: Basic Principles and Case Studies. American Psychiatric Pub; 2009.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Depression – recognition and management; 2018 Available from: https://www.nice.org.uk/guidance/cg90. Accessed 1118, 2019.
   Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. doi:10.1177/070674371665941727486148
   PubMed Web of Science ®Google Scholar
• Zimmerman M, McGlinchey JB. Why don’t psychiatrists use scales to measure outcome when treating depressed patients? J Clin Psychiatry. 2008;69(12):1916–1919. doi:10.4088/jcp.v69n120919192467
   PubMed Web of Science ®Google Scholar
• Rizvi SJ, Grima E, Tan M, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry. 2014;59(7):349–357. doi:10.1177/07067437140590070225007419
   PubMed Web of Science ®Google Scholar
• Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59(6):493–501. doi:10.1016/j.biopsych.2005.08.02216199008
   PubMed Web of Science ®Google Scholar
• Mallinckrodt Inc. Tofranil-PMTM (imipramine pamoate) [package insert]; 2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf. Accessed 1118, 2019.
   Google Scholar
• Kato T, Furukawa TA, Mantani A, et al. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUND study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Med. 2018;16(1):103. doi:10.1186/s12916-018-1096-529991347
   PubMed Web of Science ®Google Scholar
• Ruhé HG, Booij J. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology. 2009;34(4):999–1010. doi:10.1038/npp.2008.14818830236
   PubMed Web of Science ®Google Scholar
• Ho SC, Chong HY, Chaiyakunapruk N, Tangiisuran B, Jacob SA. Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: a systematic review. J Affect Disord. 2016;193:1–10. doi:10.1016/j.jad.2015.12.02926748881
   PubMed Web of Science ®Google Scholar
• Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, Moller HJ. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder – update 2015. World J Biol Psychiatry. 2015;16(2):76–95. doi:10.3109/15622975.2014.100178625677972
   PubMed Web of Science ®Google Scholar
• Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British association for psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525. doi:10.1177/026988111558109325969470
   PubMed Web of Science ®Google Scholar
• Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087–1206. doi:10.1177/000486741561765726643054
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439–1445. doi:10.1176/ps.2009.60.11.143919880458
   PubMed Web of Science ®Google Scholar
• Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One. 2013;8(10):e76882. doi:10.1371/journal.pone.007688224204694
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. Definition of treatment-resistant depression in the medicare population; 2017 Available from: https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/drafts-for-review/trd-draft.pdf. Accessed 1118, 2020.
   Google Scholar
• Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:59–67. doi:10.1016/j.jpsychires.2019.01.00330677646
   PubMed Web of Science ®Google Scholar
• Tanner J-A, Davies PE, Voudouris NC, et al. Combinatorial pharmacogenomics and improved patient outcomes in depression: treatment by primary care physicians or psychiatrists. J Psychiatr Res. 2018;104:157–162. doi:10.1016/j.jpsychires.2018.07.01230081389
   PubMed Web of Science ®Google Scholar
• Stahl S, Grady M. Stahl’s Essential Psychopharmacology: The Prescriber’s Guide. 4th ed. Cambridge University Press; 2011.
   Google Scholar